The global expansion of high-containment biolabs without oversight — increasingly engaged in Nipah virus research — combined with aggressive patent consolidation of Nipah’s core glycoproteins and their integration into mRNA and self-amplifying mRNA (saRNA) injection platforms, represents a profound and escalating global biosecurity risk.

Arecent studyidentified 3,625 Biosafety Level-3 and Level-4 laboratories worldwide:

Nipah virus is a BSL-4 pathogen with case fatality rates ranging from 40–75% in documented outbreaks. Nipah virus outbreaks haveoccurred almost every yearsince the late 1990s — primarily in Bangladesh and India.

The current situation in India being propagated by mass media involves just 2 confirmed cases, with the most recent case reported last December. This small cluster wasverified to be containeda few weeks ago.

However, accelerating Nipah virus laboratory activities, patents, and mRNA injection work raise concerns, given the Bio-pharmaceutical complex’s business model of engineering pathogens while profiting from their countermeasures.

Strangely, last weekNTD News reportedthat China is preparing Nipah virus test kits nationwide and that the Wuhan Institute of Virology announced it had identified a potential drug that could treat Nipah. It appears the infamous Wuhan Lab is currently handling Nipah virus.

According toDr. Steven Quay’s June 18, 2024 testimonybefore the Senate Committee on Homeland Security and Governmental Affairs, raw sequencing data deposited by the Wuhan Institute of Virology (WIV) in December 2019 contained evidence of work involving a Nipah virus infectious clone — specifically of the highly pathogenic Bangladesh strain.

Quay stated that the sequencing reads showed molecular features consistent with an assembled infectious clone format, including ribozyme and terminator elements typical of synthetic virology constructs. He further testified that research involving Nipah infectious clones had never been publicly reported at the WIV, raising serious questions about undisclosed synthetic biology work. Equally troubling is the documented March 2019 shipment from Canada’s National Microbiology Laboratory to Wuhan that included two strains of Nipah virus — Malaysia and Bangladesh — alongside Ebola and Hendra viruses.

There has been a sustained effort to engineer, functionalize, and embed Nipah’s G (attachment) and F (fusion) glycoproteins across successive mRNA vaccine and vector platforms. The patent and development record shows a clear escalation:

At the same time, the World Health Organization hasrepeatedly listedNipah among its priority pathogens with pandemic potential under its R&D Blueprint framework:

Source: Global Research